Devices and Diagnostics

A Record-Setting OIS

A Record-setting OIS

Last week’s Ophthalmology Innovation Summit drew nearly 1,000 attendees to Las Vegas’ Planet Hollywood hotel, marking the largest OIS event we’ve held yet. The size of the audience only added to the energy of what’s becoming a kickoff tradition for the American Academy of Ophthalmology’s annual meeting. Three dozen ophthalmology companies – representing Drug Delivery,…

Read More

Biggest OIS Ever Set to Deliver News & Insights

Biggest OIS Ever Set to Deliver News & Insights

The maturation and advance of the ophthalmology sector will be fully evident tomorrow as we host the largest Ophthalmology Innovation Summit in its seven-year history. More than 900 clinicians, investors, and executives will descend upon the Planet Hollywood Hotel in Las Vegas to grab a glimpse of novel new treatments for ophthalmology disorders. Three dozen…

Read More

Looking Deep at Extended Depth-of-Focus IOLs

Looking Deep at Extended Depth-of-Focus IOLs

Multifocal IOLs, perhaps the best established solution to the problem of enabling post-cataract patients to see clearly at all distances, work by incorporating discrete refractive optical zones or diffractive echelettes into the lens. Accommodating IOLs, which aim to provide the same benefit, use ciliary muscle power to move the lens and/or change its shape to…

Read More

FDA Making the Rounds in Ophthalmology

FDA Making the Rounds in Ophthalmology

Over the past week, news about the FDA has been flooding the inboxes of ophthalmology watchers. The most notable news came Shire plc. The regulatory agency requested that Shire conduct an additional clinical trial as part of a complete response letter for the company’s NDA for lifitegrast, a potential treatment for dry eye disease in…

Read More

Premium IOLs: Two Outliers with Mainstream Potential

Premium IOLs: Two Outliers with Mainstream Potential

A problem that plagues refractive cataract surgery is the difficulty of determining the IOL power that will achieve each patient’s refractive target. In the old days, if a post-cataract patient wasn’t satisfied with their vision, they simply wore a pair of glasses. But patients paying thousands of dollars for a premium IOL are not satisfied…

Read More

Google Lens Clinical Trials to Start in 2016

Google Lens Clinical Trials to Start in 2016

Novartis, through its Alcon eye-care division, intends to start clinical trials of an accommodative Google “smart” contact lens in human eyes next year, Novartis Chief Executive Joe Jimenez told the Swiss French-language newspaper Le Temps last week. “This project is progressing well,” Jimenez told Le Temps reporter Willy Boder. “When we announced the agreement a…

Read More

Aquesys’ CEO Details Allergan’s Successful Bid

Aquesys’ CEO Details Allergan’s Successful Bid

Last week’s sale of Aquesys represented a homecoming for CEO Ron Bache, who started his surgical device career at Allergan in the late 1990s. However, the decision to sell the privately held MIGS company to the Allergan speaks much more directly to the kind of home Allergan will be for XEN Gel Stent, Aquesys’ entry…

Read More

A Look at Premium IOLs

A Look at Premium IOLs

Can Accommodating IOLs Fuel Demand? For nearly two decades, “presbyopia-correcting” intraocular lenses (IOLs) have been available to post-cataract surgery patients, but for a variety of reasons they have garnered only modest interest. According to Market Scope, presbyopia-correcting lenses only account for 2.4% of total IOLs implanted globally in 2014. Moreover, use of these IOLs has…

Read More

Calhoun Vision Stages Turnaround

Calhoun Vision Stages Turnaround

Medtech companies in ophthalmology have made some significant strides in recent months. Second Sight and Glaukos, of course, staged IPOs in their pursuit of revolutionary ophthalmic devices. Oculeve excited Dry Eye leader Allergan enough to warrant a significant acquisition offer, bringing the highly promising neurostim device in-house where it may someday complement Restasis. Now we’re…

Read More

Cross-linking platform denied FDA approval—for now

Cross-linking platform denied FDA approval—for now

UPDATE 4/19/16: Avedro Finally Secures FDA Approval Read Full Story Click Here In late February, a joint panel of the Food and Drug Administration voted to recommend Avedro’s corneal cross-linking platform for regulatory approval. The combined riboflavin ophthalmic solutions and ultraviolet light irradiation for corneal collagen cross-linking platform may be approved for the treatment of…

Read More

Device, Delivery, & Diagnostic Company Showcase

Device, Delivery, & Diagnostic Company Showcase

Chicago—The 6th Annual Ophthalmology Innovation Summit (OIS), held here prior to the annual American Academy of Ophthalmology (AAO) featured a plethora of intriguing early- to mid-stage companies focused in the medical devices arena. A regular presenter in past OIS meetings has been Tom Frinzi, President and CEO of WaveTec Vision (Aliso Viejo, California). Frinzi has…

Read More

Alcon’s George Shares Passion for Ophthalmology

Alcon’s George Shares Passion for Ophthalmology

Chicago— Jeff George, Global Head of Alcon Inc., introduced himself to the Ophthalmology Innovation Summit community with a far-ranging keynote address, “Accelerating Innovation in Ophthalmology.” Appointed to lead Alcon in May 2014, George — who had been an executive at Alcon’s parent company, Novartis — revealed that as a youngster he had very high myopia.…

Read More